Extension Trial Assessing the Safety and Efficacy of BI 655066/ABBV-066/Risankizumab in Patients With Moderate to Severe Chronic Plaque Psoriasis

NCT02203851 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

110

Enrollment

INDUSTRY

Sponsor class

Conditions

Psoriasis

Interventions

DRUG: Risankizumab

Sponsor

AbbVie

Collaborators

[object Object]